 Galmed Pharmaceuticals Ltd. Nasdaq: GLMD Galmed or the Company, a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator AramcholTM, an oral therapy for the treatment of nonalcoholic steatohepatitis, or NASH and fibrosis, provides today updated information on the Companys clinical development program and reports financial results for the three months ended March 31, 2020. The Company will host a conference call and webcast at 08:30 ET today. 